Actualités Pasithea Therapeutics Corporation - KTTA | Actions NASDAQ

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Current Report Filing (8-k)

0001841330 false 0001841330 2023-03-10 2023-03-10 0001841330...

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual Meeting

PALO ALTO, Calif. and MIAMI, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:...

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

PALO ALTO, Calif. and MIAMI, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA...

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award

PALO ALTO, Calif. and MIAMI, Fla., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:...

Initial Statement of Beneficial Ownership (3)

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...

Current Report Filing (8-k)

0001841330 false 0001841330 2023-01-19 2023-01-19 0001841330...

Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004

-- Plans to Initiate a Phase 1 Clinical Trial in the U.S. for Neurofibromatosis Type 1 (NF1) in 2H 2023...

Amended Statement of Ownership (sc 13g/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A (Amendment No...

Amended Statement of Beneficial Ownership (sc 13d/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D &n...

Majority of Stockholders Support Pasithea Directors at Special Meeting

MIAMI BEACH, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea”...

Current Report Filing (8-k)

0001841330 false 0001841330 2022-12-09 2022-12-09 0001841330...

Amended Statement of Beneficial Ownership (sc 13d/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D &n...

Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group

MIAMI BEACH, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea”...

Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rul...

Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics

Protect the Value of Your Investment by Voting the WHITE Proxy Card Ahead of the Special Meeting Scheduled for Friday, December 9th Camac...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Pasithea Therapeutics Corporation (KTTA)

Outils de qualité professionnelle, pour des investisseurs individuels.

KTTA Actualités

Current Report Filing (8-k)

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual Meeting

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award

Initial Statement of Beneficial Ownership (3)

Current Report Filing (8-k)

Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004

Amended Statement of Ownership (sc 13g/a)

Amended Statement of Beneficial Ownership (sc 13d/a)

Majority of Stockholders Support Pasithea Directors at Special Meeting

Current Report Filing (8-k)

Amended Statement of Beneficial Ownership (sc 13d/a)

Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group

Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a)

Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Pasithea Therapeutics Corporation (KTTA) Actualités

Pasithea Therapeutics Corporation (KTTA)

Outils de qualité professionnelle, pour des investisseurs individuels.

KTTA Actualités

Current Report Filing (8-k)

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual Meeting

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award

Initial Statement of Beneficial Ownership (3)

Current Report Filing (8-k)

Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004

Amended Statement of Ownership (sc 13g/a)

Amended Statement of Beneficial Ownership (sc 13d/a)

Majority of Stockholders Support Pasithea Directors at Special Meeting

Current Report Filing (8-k)

Amended Statement of Beneficial Ownership (sc 13d/a)

Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group

Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a)

Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités